Chemodex

N-Nitrosomorpholine (NMOR)

CHF 258.00
In stock
CDX-N0370-G0011 gCHF 258.00
More Information
Product Details
Synonyms NMOR; Nitrosomorpholine; NSC-139; BRN 0112139
Product Type Chemical
Properties
Formula C4H8N2O2
MW 116.12
CAS 59-89-2
RTECS QE7525000
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (GC)
Appearance Yellow clear liquid.
Solubility Soluble in DMSO. Sligthly soluble in methanol.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key ZKXDGKXYMTYWTB-UHFFFAOYSA-N
Smiles O=NN1CCOCC1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

N-Nitrosomorpholine (NMOR) is a nitrosamine and is known to be a potent carcinogen associated with cancer development in animals and humans. NMOR can damage DNA and cause mutations in genes that control cell growth and division. It reacts with DNA in vitro to form genotoxic activity, which may lead to cell death or mutagenesis. NMOR is formed in various industrial processes, including the synthesis of certain chemicals and in the preservation of cosmetic and personal care products. This compound can be used as analytical reference material. NMOR is used as a tumor initiator. It is a reagent for preparing carcinogenic animal diseases model. NMOR has other widespread utilization in laboratory and industrial environments. NMOR exhibits potent oxidizing properties, making it valuable in various applications, including as a bulding block for synthesis, environmental monitoring, and as a reagent in laboratory settings. It serves as a vital component in the synthesis of diverse compounds and functions as an analytical reagent.

Product References

(1) H.S. Taper, et al.; Cancer Res. 31, 913 (1971) | (2) R. Prakin, et al.; Mutat. Res. 21, 155 (1973) | (3) C.E. Kimble, et al.; Mutat. Res. 31, 153 (1975) | (4) K.D. Brunnemann, et al.; Carcinogenesis 3, 693 (1982) | (5) J.B. Morrison & S.S. Hecht; IARC Sci. Publ. 57, 185 (1984) | (6) R.G. Klein, et al.; Exp. Pathol. 40, 189 (1990) | (7) P.A. Munzel, et al.; Biochem. Pharnacol. 42, 365 (1991) | (8) S. Tudzarova-Trajkovska & J. Wesierska-Gadek; J. Cell Biochem. 90, 837 (2003) | (9) S. Robichova, et al.; Chem. Biol. Interact. 148, 163 (2004) | (10) C.M. Glover, et al.; Water Res. 148, 306 (2019) | (11) Y. Li & S.S. Hecht; Int. J. Mol. Sci. 23, 4559 (2022) | (12) M. Bignami, et al.; Efsa J. 21, e07884 (2023)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.